TMCnet News

Downgrade Alert for Myriad Genetics (MYGN)
[December 03, 2012]

Downgrade Alert for Myriad Genetics (MYGN)


Dec 03, 2012 (SmarTrend(R) Upgrades/Downgrades via COMTEX) -- Myriad Genetics (NASDAQ:MYGN) was downgraded from Buy to Neutral at Mizuho today. The stock closed yesterday at $28.72 on volume of 3.9 million shares, above average daily volume of 715,000. Potential upside of 5.7% exists for Myriad Genetics, based on a current level of $28.72 and analysts' average consensus price target of $30.36. The stock should find initial support at its 50-day moving average (MA) of $27.36 and further support at its 200-day MA of $25.24.



In the past 52 weeks, Myriad Genetics share prices have been bracketed by a low of $17.51 and a high of $31.80 and closed yesterday at $28.72, 64% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 1.1% while the 200-day MA has risen 0.4%.

Myriad Genetics, Inc. develops and markets molecular diagnostic products to provide physicians with information to help guide the care of their patients, to prevent disease, delay the onset of disease, or catch disease at an early stage.


SmarTrend is tracking the current trend status for Myriad Genetics and will alert subscribers who have MYGN in their portfolio or watchlist when shares have changed trend direction.

Write to Chip Brian at [email protected] --------------------------------------------------------------------------------------------- SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.MySmarTrend.com Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.MySmarTrend.com/signup

[ Back To TMCnet.com's Homepage ]